Black Diamond Therapeutics, Inc.

BDTX

$2.10

-1.87%

N/A-$0.04

Healthcare

Biotechnology

NASDAQ

Active Trading

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients ...

Financial Highlights of BDTX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-2.84x

n/a

Debt / Equity

0.18

n/a

Current Ratio

7.28

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-2.84x

Debt / Equity

0.18

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	99.5%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	28.4%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	32.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	0.0%	0.0%	32.4%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	32.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	9.12	8.37	6.82	4.92	8.42	—
Quick RatioLiquid assets divided by current liabilities.	9.12	8.37	6.82	4.92	8.42	—
Cash RatioCash and equivalents divided by current liabilities.	2.78	2.25	2.86	1.77	1.33	—
Debt / AssetsDebt as a share of total assets.	11.5%	18.0%	16.0%	18.1%	13.1%	—
Debt / EquityDebt compared with shareholder equity.	0.15	0.24	0.22	0.27	0.17	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.19x	0.00x	0.56x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.00x	0.00x	0.49x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.00x	0.00x	0.71x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-1.54x	-0.71x	-1.49x	-1.69x	6.23x	—
P/B RatioPrice paid for each dollar of book value.	0.98x	0.56x	1.06x	1.41x	1.23x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	0.00x	0.00x	1.97x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-1.88x	-0.76x	-1.85x	-1.89x	4.67x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

Contract Manufacturing Organizations (CDMOs) — Small Molecule API & Drug ProductContract Research Organizations (CROs)OpenEye, Cadence Molecular Sciences (Cadence Design Systems)NASDAQ:CDNSSpecialty Chemical & Raw Material Suppliers (via CDMOs)

Downstream

Servier Pharmaceuticals LLC (Laboratoires Servier)Potential Future Partner(s) for Silevertinib (BDTX-1535)

Proxies

Blueprint Medicines CorporationNASDAQ:BPMC Relay Therapeutics, Inc.NASDAQ:RLAY Schrödinger, Inc.NASDAQ:SDGR Nuvalent, Inc.NASDAQ:NUVL

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Black Diamond Therapeutics, Inc.

Financial Highlights of BDTX

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of BDTX

Upstream

Downstream

Proxies

Financial Highlights of BDTX

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of BDTX

Upstream

Downstream

Proxies